Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Interest & Investment Income (2018 - 2025)

Arcus Biosciences has reported Interest & Investment Income over the past 8 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $10.0 million for Q4 2025, down 16.67% from a year ago — trailing twelve months through Dec 2025 was $41.0 million (down 21.15% YoY), and the annual figure for FY2025 was $41.0 million, down 21.15%.
  • Interest & Investment Income for Q4 2025 was $10.0 million at Arcus Biosciences, roughly flat from $10.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for RCUS hit a ceiling of $14.0 million in Q3 2024 and a floor of $154000.0 in Q1 2021.
  • Median Interest & Investment Income over the past 5 years was $9.5 million (2023), compared with a mean of $7.6 million.
  • Biggest five-year swings in Interest & Investment Income: plummeted 76.2% in 2021 and later surged 3005.59% in 2022.
  • Arcus Biosciences' Interest & Investment Income stood at $519000.0 in 2021, then surged by 1441.43% to $8.0 million in 2022, then soared by 37.5% to $11.0 million in 2023, then grew by 9.09% to $12.0 million in 2024, then decreased by 16.67% to $10.0 million in 2025.
  • The last three reported values for Interest & Investment Income were $10.0 million (Q4 2025), $10.0 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.